PL1896470T3 - Pochodne pirolopirydynowe jako inhibitory kinazy białkowej - Google Patents
Pochodne pirolopirydynowe jako inhibitory kinazy białkowejInfo
- Publication number
- PL1896470T3 PL1896470T3 PL06759904T PL06759904T PL1896470T3 PL 1896470 T3 PL1896470 T3 PL 1896470T3 PL 06759904 T PL06759904 T PL 06759904T PL 06759904 T PL06759904 T PL 06759904T PL 1896470 T3 PL1896470 T3 PL 1896470T3
- Authority
- PL
- Poland
- Prior art keywords
- compounds
- protein kinase
- kinase inhibitors
- pyrrolopyridine derivatives
- disorders
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000005255 pyrrolopyridines Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- -1 CAMKII Proteins 0.000 abstract 1
- 108091007914 CDKs Proteins 0.000 abstract 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 101150009057 JAK2 gene Proteins 0.000 abstract 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000005441 aurora Substances 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000011435 rock Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68185305P | 2005-05-16 | 2005-05-16 | |
| EP06759904A EP1896470B1 (en) | 2005-05-16 | 2006-05-15 | Pyrrolopyridine derivatives as protein kinase inhibitors |
| PCT/US2006/018868 WO2006124863A2 (en) | 2005-05-16 | 2006-05-15 | Pyrrolopyridine derivatives as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1896470T3 true PL1896470T3 (pl) | 2011-03-31 |
Family
ID=37076087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06759904T PL1896470T3 (pl) | 2005-05-16 | 2006-05-15 | Pochodne pirolopirydynowe jako inhibitory kinazy białkowej |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080300267A1 (pl) |
| EP (1) | EP1896470B1 (pl) |
| JP (1) | JP2008540664A (pl) |
| KR (1) | KR20080016643A (pl) |
| CN (1) | CN101218241B (pl) |
| AT (1) | ATE469151T1 (pl) |
| AU (1) | AU2006247322A1 (pl) |
| BR (1) | BRPI0610828A2 (pl) |
| CA (1) | CA2608333A1 (pl) |
| DE (1) | DE602006014540D1 (pl) |
| ES (1) | ES2345629T3 (pl) |
| MX (1) | MX2007014327A (pl) |
| PL (1) | PL1896470T3 (pl) |
| PT (1) | PT1896470E (pl) |
| RU (1) | RU2387653C2 (pl) |
| WO (1) | WO2006124863A2 (pl) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4937112B2 (ja) | 2004-03-30 | 2012-05-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール |
| US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| AU2005269386A1 (en) | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| SG156685A1 (en) | 2004-07-27 | 2009-11-26 | Sgx Pharmaceuticals Inc | Fused ring heterocycle kinase modulators |
| US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| EP1881983B1 (en) * | 2005-05-20 | 2012-01-11 | Vertex Pharmaceuticals, Inc. | Pyrrolopyridines useful as inhibitors of protein kinase |
| BRPI0706537A2 (pt) | 2006-01-17 | 2011-03-29 | Vertex Pharma | azaindóis úteis como inibidores de janus cinases |
| DE102006012617A1 (de) * | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| JP2009537621A (ja) * | 2006-05-22 | 2009-10-29 | アストラゼネカ アクチボラグ | インドール誘導体 |
| CA2668159A1 (en) * | 2006-11-01 | 2008-07-03 | Vertex Pharmaceuticals Incorporated | Tricyclic heteroaryl compounds useful as inhibitors of janus kinase |
| JP5179509B2 (ja) | 2006-12-08 | 2013-04-10 | エフ．ホフマン−ラ ロシュ アーゲー | 置換ピリミジン類及びｊｎｋモジュレーターとしてのこれらの使用 |
| KR20090091350A (ko) | 2006-12-21 | 2009-08-27 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로 유용한 ５-시아노-４-피롤로[２,３ｂ]피리딘-３-일)-피리디민 유도체 |
| JP2010514688A (ja) * | 2006-12-22 | 2010-05-06 | ノバルティス アーゲー | インドール−４−イルピリミジニル−２−イル−アミン誘導体およびサイクリン依存性キナーゼ阻害剤としてのその使用 |
| FR2912744B1 (fr) * | 2007-02-16 | 2012-09-07 | Centre Nat Rech Scient | Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations. |
| CN101679436A (zh) | 2007-04-10 | 2010-03-24 | Sgx药品公司 | 稠环杂环激酶调节剂 |
| TW200908968A (en) | 2007-05-29 | 2009-03-01 | Sgx Pharmaceuticals Inc | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators |
| GB0710528D0 (en) * | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| HUE055524T2 (hu) * | 2007-06-01 | 2021-11-29 | Wyeth Llc | A bcrabl génben 1457T>C mutációt tartalmazó, imatinibbel szemben ellenálló krónikus mielogén leukémia kezelése bozutinib vegyület alkalmazásával |
| DE102007028515A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
| KR20100093552A (ko) * | 2007-11-02 | 2010-08-25 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 ｃ-세타로서의 [1ｈ-피라졸로[3,4-ｂ]피리딘-4-일]-페닐 또는 -피리딘-2-일 유도체 |
| BRPI0907236A2 (pt) * | 2008-01-22 | 2017-06-06 | Merck Patent Ges Mit Berschränkter Haftung | inibidores de proteína quinase e uso dos mesmos |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP3210609A1 (en) | 2008-05-21 | 2017-08-30 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| EP2671891A3 (en) | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| DE102008031517A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| CA2731451A1 (en) * | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| WO2010011772A2 (en) * | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| CN101723936B (zh) * | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| CA2760705A1 (en) * | 2009-05-06 | 2010-11-11 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| IL299019A (en) | 2009-05-26 | 2023-02-01 | Abbvie Ireland Unlimited Co | Process for preparing 2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-en-8-yl)methyl)piperazin-1-yl)benzoic acid |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| SI2442809T1 (sl) | 2009-06-17 | 2017-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji replikacije virusov gripe |
| US8779142B2 (en) * | 2009-07-10 | 2014-07-15 | Taiho Pharmaceutical Co., Ltd. | Azabicyclo compound and salt thereof |
| CA2767089A1 (en) * | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyridine inhibitors of kinases |
| DE102009060175A1 (de) * | 2009-12-23 | 2011-06-30 | Merck Patent GmbH, 64293 | Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen |
| CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2011094273A1 (en) | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| MX2012008643A (es) | 2010-01-27 | 2013-02-26 | Vertex Pharma | Inhibidores de cinasas de pirazolopiridinas. |
| JP2013518113A (ja) | 2010-01-27 | 2013-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾロピラジンキナーゼ阻害剤 |
| US20120277210A1 (en) | 2010-10-29 | 2012-11-01 | Abbott Laboratories | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US20120129853A1 (en) | 2010-11-23 | 2012-05-24 | Abbott Laboratories | Methods of treatment using selective bcl-2 inhibitors |
| SI2643322T1 (en) | 2010-11-23 | 2018-01-31 | Abbvie Inc. | Salts and crystalline forms of an apoptosis induction agent |
| WO2012083117A1 (en) | 2010-12-16 | 2012-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| KR20130128435A (ko) * | 2010-12-16 | 2013-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| KR20130128436A (ko) * | 2010-12-16 | 2013-11-26 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| CA2832504C (en) | 2011-05-04 | 2019-10-01 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| US10138235B2 (en) | 2011-12-14 | 2018-11-27 | Sanofi | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
| FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
| WO2013116291A1 (en) * | 2012-01-30 | 2013-08-08 | Cephalon, Inc. | Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| MX2014014828A (es) * | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Compuestos de 5-azaindazol y metodos de uso. |
| WO2014063068A1 (en) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| FR3000493A1 (fr) * | 2012-12-28 | 2014-07-04 | Oribase Pharma | Nouveaux inhibiteurs de proteines kinases |
| JP6318180B2 (ja) * | 2013-03-06 | 2018-04-25 | アロステロス セラピューティクス， インコーポレイテッド | ＣａＭＫＩＩ阻害剤及びその使用 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2014155300A2 (en) * | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Substitued pyrimidine amine derivatives as tak-1 inhibitors |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| JP6491202B2 (ja) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤 |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| AU2014348752C1 (en) | 2013-11-13 | 2019-11-21 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| MX382171B (es) | 2013-11-13 | 2025-03-13 | Vertex Pharmaceuticals Incorporated | Inhibidores de replicacion del virus de influenza. |
| CN104860941B (zh) * | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| EP3189052B1 (en) * | 2014-09-05 | 2021-11-03 | The Johns Hopkins University | Camkii inhibitors and uses thereof |
| MA40772A (fr) | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus de la grippe a |
| MA40773A (fr) | 2014-10-02 | 2017-08-08 | Vertex Pharma | Variants du virus influenza a |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US20180263979A1 (en) * | 2014-12-23 | 2018-09-20 | Millennium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| EP3273966B1 (en) | 2015-03-27 | 2023-05-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JP7352284B2 (ja) * | 2017-05-15 | 2023-09-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体 |
| CA3099763A1 (en) | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| CN112142731B (zh) * | 2019-06-28 | 2022-07-22 | 成都赜灵生物医药科技有限公司 | 一种2，4-二取代嘧啶衍生物及其制备方法和用途 |
| WO2021018820A1 (en) * | 2019-07-29 | 2021-02-04 | Heparegenix Gmbh | Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN110627775A (zh) * | 2019-10-24 | 2019-12-31 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN114452392B (zh) * | 2022-02-07 | 2024-06-18 | 孙良丹 | 用于抑制camk2g表达的制剂在制备用于治疗银屑病的药剂中的应用 |
| CN115785134B (zh) * | 2022-10-28 | 2023-08-29 | 浙大城市学院 | 一种含氮杂环的硼酸化合物及制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7132998A (en) * | 1997-04-24 | 1998-11-13 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
| WO2002004447A1 (en) * | 2000-07-11 | 2002-01-17 | Pharma Mar, S.A. | Variolin derivatives as anti-cancer agents |
| SE0202463D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| JP4937112B2 (ja) * | 2004-03-30 | 2012-05-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
-
2006
- 2006-05-15 AT AT06759904T patent/ATE469151T1/de active
- 2006-05-15 MX MX2007014327A patent/MX2007014327A/es not_active Application Discontinuation
- 2006-05-15 PL PL06759904T patent/PL1896470T3/pl unknown
- 2006-05-15 RU RU2007146390/04A patent/RU2387653C2/ru not_active IP Right Cessation
- 2006-05-15 DE DE602006014540T patent/DE602006014540D1/de active Active
- 2006-05-15 KR KR1020077029309A patent/KR20080016643A/ko active IP Right Grant
- 2006-05-15 PT PT06759904T patent/PT1896470E/pt unknown
- 2006-05-15 BR BRPI0610828-8A patent/BRPI0610828A2/pt not_active IP Right Cessation
- 2006-05-15 JP JP2008512430A patent/JP2008540664A/ja active Pending
- 2006-05-15 CA CA002608333A patent/CA2608333A1/en not_active Abandoned
- 2006-05-15 CN CN2006800250087A patent/CN101218241B/zh not_active Expired - Fee Related
- 2006-05-15 US US11/914,210 patent/US20080300267A1/en not_active Abandoned
- 2006-05-15 WO PCT/US2006/018868 patent/WO2006124863A2/en active Application Filing
- 2006-05-15 ES ES06759904T patent/ES2345629T3/es active Active
- 2006-05-15 EP EP06759904A patent/EP1896470B1/en not_active Not-in-force
- 2006-05-15 AU AU2006247322A patent/AU2006247322A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007014327A (es) | 2008-02-11 |
| RU2007146390A (ru) | 2009-06-27 |
| AU2006247322A1 (en) | 2006-11-23 |
| EP1896470B1 (en) | 2010-05-26 |
| US20080300267A1 (en) | 2008-12-04 |
| CN101218241B (zh) | 2011-02-16 |
| JP2008540664A (ja) | 2008-11-20 |
| ES2345629T3 (es) | 2010-09-28 |
| BRPI0610828A2 (pt) | 2010-07-27 |
| CN101218241A (zh) | 2008-07-09 |
| CA2608333A1 (en) | 2006-11-23 |
| PT1896470E (pt) | 2010-08-26 |
| WO2006124863A2 (en) | 2006-11-23 |
| KR20080016643A (ko) | 2008-02-21 |
| DE602006014540D1 (en) | 2010-07-08 |
| RU2387653C2 (ru) | 2010-04-27 |
| ATE469151T1 (de) | 2010-06-15 |
| WO2006124863A3 (en) | 2007-01-25 |
| EP1896470A2 (en) | 2008-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1896470T3 (pl) | Pochodne pirolopirydynowe jako inhibitory kinazy białkowej | |
| TW200637547A (en) | Compounds and compositions as protein kinase inhibitors | |
| TNSN06053A1 (en) | 6-substituted anilino purines as rtk inhibitors | |
| MX2009004716A (es) | Compuestos y composiciones en la forma de inhibidores de quinasa de proteina. | |
| MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| MXPA05010711A (es) | Compuestos y composiciones novedosos como inhibidores de proteina-quinasa. | |
| MX2009011950A (es) | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| MX2008002165A (es) | Compuestos y composiciones como inhibidores de la proteina cinasa. | |
| WO2004078682A3 (en) | Cyclic compounds and compositions as protein kinase inhibitors | |
| NO20071915L (no) | Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer | |
| TW200801008A (en) | Protein kinase inhibitors | |
| PL1899329T3 (pl) | Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych | |
| TW200610762A (en) | Compounds and compositions as protein kinase inhibitors | |
| WO2009097287A9 (en) | Compounds and compositions as kinase inhibitors | |
| BRPI0517015A (pt) | compostos e composições como inibidores de atividade de receptor 1 de canabinóide | |
| TN2012000081A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
| MX2009006170A (es) | Compuestos y composiciones como inhibidores de cinasa. | |
| IL184898A0 (en) | Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same | |
| DK1951729T3 (da) | Oxygenbundne pyrimidinderivater | |
| MX2008001605A (es) | Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica. | |
| MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| IL188942A0 (en) | Benzimidazole derivatives and pharmaceutical compositions containing the same | |
| WO2005039486A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. |